Table 2.
Completed Phase II Trials of Single-Agent Targeted Therapies for Advanced or Recurrent Endometrial Carcinoma
| Drug | Target | Number of Patients | Prior Chemotherapy Regimens | Route | CR (%) | PR (%) | SD (%) |
|---|---|---|---|---|---|---|---|
| Temsirolimus27 | mTOR | 29 | 0 | IV | 0 | 14 | 69 |
| Temsirolimus27 | mTOR | 25 | 1 | IV | 0 | 7.4 | 44 |
| Everolimus29 | mTOR | 28 | 1–2 | PO | 0 | 0 | 42.9 |
| Ridaforolimus31 | mTOR | 27 | 0 | PO | 0 | 7.7 | 58 |
| Bevacizumab47 | VEGF | 52 | 1–2 | IV | 1.9 | 11.5 | 40.4 |
| Thalidomide51 | VEGF | 24 | ≤1 | PO | 0 | 12.5 | 8.3 |
| Sunitinib49 | VEGFR | 20 | ≤1 | PO | 0 | 15 | 25 |
| Sorafenib50 | VEGFR | 39 | ≤1 | PO | 0 | 5 | 49 |
| Erlotinib54 | EGFR | 32 | 0 | PO | 0 | 12.5 | 46.9 |
| Cetuximab55 | EGFR | 30 | ≥1 | IV | 0 | 5 | 10 |
| Gefitinib56 | EGFR | 26 | 1–2 | PO | 0 | 4 | 27 |
| Trastuzumab59 | HER2 | 34 | No limit | IV | 0 | 0 | 35.3 |
CR=complete response; EGFR=epidermal growth factor receptor; HER2=human epidermal growth factor receptor 2; IV=intravenous; mTOR=mammalian target of rapamycin; PO=oral; PR=partial response; SD=stable disease; VEGF=vascular endothelial growth factor; VEGFR=vascular endothelial growth factor receptor.